A Study to Confirm Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis

Inclusion Criteria:

• Male or female subjects aged 18 years and older

• Diagnosis of plaque psoriasis for at least 6 months

• Eligible for phototherapy or systemic therapy

• Plaque covering ≥ 10% of BSA

• PASI ≥ 12, sPGA ≥3

Exclusion Criteria:

• Diagnosis of non-plaque psoriasis or drug-induced psoriasis

• Recent history of infection, history or risk of serious infection

• Any major illness or evidence of unstable condition of major organ systems includingpsychiatric disease

• Any condition possibly affecting the PK process of the study drug

• Evidence of other skin conditions that would interfere with the evaluation ofpsoriasis

• History of hypersensitivity to the ingredients of study drugs, history ofanaphylaxis

• Prior exposure to TYK2 inhibitors

• Have received the prohibited treatment during the protocol required washout period

• Any significant laboratory or procedure abnormalities that might place the subjectat unacceptable risk during this study period